Journey Medical Corporation

NASDAQ:DERM

Drug Manufacturers - Specialty & Generic

Healthcare
$3.69 +0.99%

+$0.06 today

Market cap
$104.15M
Beta
1.10
P/E (TTM)
-17.0
EPS (TTM)
-$0.35
52W Low $4.31High $9.56

Volume 0.25M

Average 0.28M

DERM Gross Margin

Gross profit as a percentage of revenue, showing how much of each sales dollar is kept after direct costs.

Journey Medical CorporationNASDAQ: DERM

Gross Margin · Q1 FY2026 · quarter ended Mar 2026

Gross margin narrows to 54.0%

Gross margin was 54.0% in Q1 FY2026, down 1.5 pp from a year earlier. On a trailing-twelve-month basis it was 60.4%, down 4.2 pp year over year. Over 3 fiscal years it widened by 1.1 pp.

Context

  • Gross margin widened in 1 of the last 3 fiscal years.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
54.0%-5.6 pp QoQ
Last fiscal yearDec 2025
59.3%-3.5 pp YoY
LTMMar 2026
60.4%-4.2 pp YoY
Gross Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter-1.5 pp——
1 year-3.5 pp——
3 years+1.1 pp——
5 years——
10 years——

Gross Margin history

Percent of revenue · from the income statement

Latest · FY2025
59.3%
Year-over-year change
-3.5pp

Gross Margin vs competitors

How DERM compares with its peers on the latest reported figures

  • DERM's LTM Mar 2026 gross margin of 60.4% is the 4th highest of the 10 companies compared; the peer median is 41.0%.
  • Its year-over-year change of -4.2 pp is the 7th highest of 10, against a peer median of +2.0 pp.
  • Over three fiscal years its change of +1.1 pp compares with a peer median of +1.1 pp.
DERM Competitors Peer median
Gross Margin for DERM and competitors
Company Period LTM level YoY 3-year change
OBIOOrchestra BioMed Holdings, Inc.LTM Mar 202699.3% +6.7 pp+8.5 pp
HSDTSolana CompanyLTM Mar 202694.2% +127.8 pp+50.5 pp
FENCFennec Pharmaceuticals Inc.LTM Mar 202692.2% +2.0 pp-2.8 pp
DERMJourney Medical CorporationLTM Mar 202660.4% -4.2 pp+1.1 pp
NYXHNyxoah S.A.LTM Mar 202648.3% -17.2 pp+0.4 pp
OSUROraSure Technologies, Inc.LTM Mar 202641.0% -1.5 pp+3.6 pp
OGIOrganigram Global Inc.LTM Mar 202635.6% +2.9 pp—
IVAInventiva S.A.FY202533.7% -66.3 pp-106.4 pp
MDWDMediWound Ltd.LTM Mar 202619.6% +5.2 pp-30.5 pp
RNACCartesian Therapeutics, Inc.LTM Mar 2026-621.0% -721.0 pp+1.8 pp
Peer median (excluding DERM) 41.0%+2.0 pp+1.1 pp

Competitors are the stored peer set for DERM. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue63.13M73.67M79.18M56.13M61.86M
Cost of Revenue32.08M30.78M26.66M20.88M25.18M
Gross Profit31.05M42.89M52.52M35.26M36.68M
Gross Margin49.2%58.2%66.3%62.8%59.3%
Research & Development16.56M10.94M7.54M9.86M480K
Selling, General & Admin39.83M59.47M43.91M40.2M44.37M
Operating Expenses65.93M70.41M54.59M48.93M44.85M
Depreciation & Amortization2.56M4.37M3.86M3.52M4.35M
EBITDA(32.77M)(23.18M)1.92M(8.4M)(3.33M)
EBITDA Margin-51.9%-31.5%2.4%-15.0%-5.4%
Operating Income(34.88M)(27.52M)(2.07M)(13.68M)(8.17M)
Operating Margin-55.2%-37.4%-2.6%-24.4%-13.2%
Interest Income2K60K322K757K589K
Interest Expense7.03M2.02M1.7M2.7M3.7M
Other Income / Expenses(7.48M)(2.05M)(1.56M)(934K)(3.2M)
Income Before Tax(42.36M)(29.57M)(3.63M)(14.61M)(11.37M)
Pre-Tax Margin-67.1%-40.1%-4.6%-26.0%-18.4%
Income Tax Expense1.63M63K221K61K60K
Net Income(43.99M)(29.63M)(3.85M)(14.67M)(11.43M)
Net Margin-69.7%-40.2%-4.9%-26.1%-18.5%
EPS (Basic)(2.54)(1.69)(0.21)(0.72)(0.47)
EPS (Diluted)(2.54)(1.69)(0.21)(0.72)(0.47)
Weighted Avg Shares17.32M17.53M18.23M20.43M24.5M
Weighted Avg Shares (Diluted)17.32M17.53M18.23M20.43M24.5M

Journey Medical Corporation

NASDAQ:DERM

Intrinsic Alpha fair value

Locked

Current Price

$3.69

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.